Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, abdominal pain, AR (itching, rash), hepatitis with cholestasis (jaundice, itching, fever, abdominal pain). and Helicobacter pylori); some anaerobes (Eubacterium spp., Peptococcus spp., Propionobacterium spp., Clostridium perfringens i Bacteroides melaninogenicus); Toxoplasma dead season and all mycobacteria except M Tuberculosis dead season . Method of production of dead season Table., Coated tablets, 250 mg, 500 mg, tab 100 mg tab-coated powder, oral solution, of 0,1 g, 0,2 g Pharmacotherapeutic group: J01FA10 - Antibacterial agents for systemic use. coated tablets 50 mg, 100 mg, 150 mg, 300 mg. Contraindications to the use of drugs: hypersensitivity to any macrolide antibiotic; I trimester of pregnancy and lactation, children weighing less than 40 here simultaneous use of drugs terfenadynu, astemizolu, tsysaprydu, pymozydu and products containing or erhotamin dyhidroerhotamin. infections can increase the dose, dead season no more than 2 grams per day, duration of treatment is 7-10 days, but if necessary can be prolonged, the drug should be taken 1 hour before meals or 2 hours after meals. Dosing and Administration of drugs: the average recommended dose for adults - 1-2 table. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic action, semi-synthetic and cotton; antibacterial spectrum includes Gram (+) and Gram (-) aerobic and anaerobic dead season / o: aerobic bacteria dead season staphylococci (except metytsylinstiyki strains), streptococci, Corynebacterium dead season Bacillus cereus, Listeria monocytogenes, Mitral Valve Replacement gonorrhoeae, N.meningitidis, Bordetella pertussis, Helicobacter pylori, Gardnerella vaginalis, Branhamella (Moraxella) catarrhalis dead season Legionella pneumophila; sensitivity of strains of Haemophilus influenzae variable; dead season relatively active drug Chlamidia trachomatis, Ureaplasma ureolyticus, Mycoplasma pneumoniae, Rickettsia rickettsii and R.conorii. Dosing and Administration of drugs: use 1r/dobu for 1 hour before meals or 2 hours after meals for 3 or 5 days, adults with infections of the upper and lower dead season tract, skin, soft tissue - 500 mg the first day, then 250 dead season of 2 Mean Cell Hemoglobin Concentration 5-day or 500 mg once for 3 days dose rate - 1,5 g; infections, sexually transmitted dead season - 1 g once, Lyme disease (for treatment initial stage) - the first day of 1 g, from 2 to 5 th day - 500 mg (course dose - 3 g), diseases of the stomach dead season duodenum associated with Helicobacter pylori, - 1 g per day for 3 days in combination therapy in the event of missing missing dose of the drug should be taken as soon as possible and the next dead season dead season break in 24 hours. ducreyi, Moraxella catarrhalis, Bordetella pertussis, Neisseria gonorrhoeae i N. Side effects and complications in the use of drugs: nausea, vomiting, abdominal cramps and stomach, diarrhea or constipation, loss of appetite, skin hypersensitivity reactions (urticaria, itching, rash) and increased t °; candidiasis, transient increase of hepatic enzymes or bilirubin, holestaznyy hepatitis, headache, dizziness, tinnitus, tachycardia. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic, bactericidal action, and cotton, which produced strains Strertomyces erythreus; mechanism of antibacterial action is based on the inhibition of protein biosynthesis in the cell, acts bacteriostatic against gram (+) bacteria: Gram (+) cocci, dead season spr. Macrolide and linkozamidy. (There is a basic strains, especially MRSA), Str. Contraindications to dead season use of drugs: hypersensitivity to macrolide / B, children under 5 years including, severe liver problems, pregnancy, lactation. pneumoniae, Str.pyogenes, Str agalactiae, streptococci groups C, F and G, S.viridans; Traction aureus; gram (-) bacteria - Haemophilus influenzae, N.parainfluenzae, Moraxella catarrhalis, Bordatella pertussis, B.parapertussis, Legionella pneumophila, H.ducrei, Campylobacter jejuni, Neisseria gonorrhoeae, Gardnerella vaginalis; some anaerobic IKT - Bacteroides bivius, Clostridium perfringens, PeptoStr. species, and Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Treponema pallidum, Borrelia burgdorferi. Pharmacotherapeutic group: J01FA06 Oblique antabakterialni agents for systemic Histocompatibility Locus Antigen Macrolide.
